title: Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
abstract: BACKGROUND
  The use of direct-acting antiviral (DAA) agents against chronic hepatitis C virus (HCV) infections can result in the successful treatment of nearly all patients. Effective antiviral treatments can prevent the progression to cirrhosis and hepatocellular malignancy, and decrease liver-related morbidity and mortality.
  
  
  METHODS
  Paritaprevir-ritonavir-ombitasvir and dasabuvir (PrOD), with or without ribavirin, is an all-oral regimen approved for the treatment of HCV genotype 1 infections, including patients with compensated cirrhosis. Phase 2 and 3 clinical trials demonstrated the safety and efficacy of this regimen in HCV genotype 1-infected patients who are treatment-naïve and those who have failed peginterferon/ribavirin therapy. Additional studies evaluated the use of PrOD with or without ribavirin among special populations, including patients co-infected with human immunodeficiency virus-1 and HCV, liver transplant recipients with HCV recurrence, and patients with severe renal impairment. Additionally, the combination of paritaprevir-ritonavir-ombitasvir plus ribavirin is found to be highly efficacious, and is now approved in the US, for the treatment of HCV genotype 4 infections.
  
  
  CONCLUSIONS
  The availability and use of interferon-free DAA combination regimens has resulted in a major paradigm shift in the treatment of HCV. PrOD, with or without ribavirin, is an effective, safe and tolerable treatment option.
authors.affiliation: a Department of Surgery , University of California Los Angeles , Los Angeles , CA , USA.
authors.forename: Elaine Y
authors.initials: EY
authors.lastname: Cheng
authors.affiliation: b Departments of Medicine and Surgery , University of California Los Angeles , Los Angeles , CA , USA.
authors.forename: Sammy
authors.initials: S
authors.lastname: Saab
authors.affiliation: a Department of Surgery , University of California Los Angeles , Los Angeles , CA , USA.
authors.forename: Curtis D
authors.initials: CD
authors.lastname: Holt
authors.affiliation: a Department of Surgery , University of California Los Angeles , Los Angeles , CA , USA.
authors.forename: Ronald W
authors.initials: RW
authors.lastname: Busuttil
mesh_terms: D015081:2-Naphthylamine; D000813:Anilides / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D002219:Carbamates / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D060085:Coinfection; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications; D015497:HIV-1; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D047029:Lactams, Macrocyclic; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000209:etiology; D047028:Macrocyclic Compounds / Q000627:therapeutic use*; D011392:Proline / Q000031:analogs & derivatives; D012254:Ribavirin / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D014498:Uracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014633:Valine
chemical_list: D000813:Anilides; D000998:Antiviral Agents; D002219:Carbamates; D003521:Cyclopropanes; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds; D013449:Sulfonamides; C586094:ombitasvir; D012254:Ribavirin; D014498:Uracil; D011392:Proline; D015081:2-Naphthylamine; C588260:dasabuvir; D014633:Valine; D019438:Ritonavir; C585405:paritaprevir
keywords: dasabuvir; direct acting antiviral agents; hepatitis C; ombitasvir; paritaprevir; sustained virologic response